QRG Capital Management Inc. Purchases 5,863 Shares of Edwards Lifesciences Corporation $EW

QRG Capital Management Inc. raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 10.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,327 shares of the medical research company’s stock after purchasing an additional 5,863 shares during the quarter. QRG Capital Management Inc.’s holdings in Edwards Lifesciences were worth $4,831,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after buying an additional 371,892 shares during the period. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the period. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $803,686,000. Morgan Stanley raised its holdings in shares of Edwards Lifesciences by 12.4% in the fourth quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after buying an additional 804,942 shares during the period. Finally, Marshall Wace LLP lifted its stake in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $94.31 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market capitalization of $54.31 billion, a PE ratio of 50.17, a P/E/G ratio of 2.37 and a beta of 0.86. The company has a 50 day moving average price of $85.61 and a 200-day moving average price of $83.57. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $94.47.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a report on Wednesday, April 1st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.39.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $91.40, for a total value of $56,576.60. Following the completion of the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,693,565.40. The trade was a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 57,958 shares of company stock valued at $4,839,284 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.